Express News | Altamira Therapeutics Ltd - Merged Entity Will Be Called Altamira Therapeutics AG and Continue to Serve as Core Operating Subsidiary of Company
Express News | Altamira Therapeutics Provides Business Update On RNA Delivery Platform; Announces Improvement In RNA Nanoparticle Stability, Pursues Partnering Opportunities For AM-125 In Vertigo And CNS Indications, And Switches Financial Reporting From Swiss...
Express News | Altamira Therapeutics Ltd - Co Is About to Merge Two of Its Subsidiaries in Basel (Switzerland), Auris Medical AG and Altamira Therapeutics AG
Express News | Altamira Therapeutics Ltd - Streamlining Corporate Structure; Switch in Financial Reporting From Swiss Francs to US Dollars
Altamira Therapeutics Provides Business Update
Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticlesPursuing partnering opportunities with AM-125 legacy asse
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
PALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis,
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersOneMedNet (NASDAQ:ONMD) shares moved upwards by 118.4% to $1.07 during Thursday's regular session. The market value of their outstanding shares is at $25.5 million. Renovaro (NASDAQ:RENB) stock
Express News | Altamira Therapeutics Shares Are Trading Higher After Highlights From Its NASAR Clinical Trial With Bentrio Nasal Spray Were Published in Video Format on the Social Media Channels of the Journal, "Allergy."
What's Going On With Altamira Therapeutics Stock?
Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares are trading higher Thursday after the company announced highlights from its NASAR clinical trial with Bentrio nasal spray were published in video format
Jaguar Health, Altamira Therapeutics,Erasca Among Healthcare Movers
Altamira Stock Soars 45% on Bentrio Social Media Postings
Express News | Altamira Therapeutics Announces Publication Of Highlights From The NASAR Clinical Trial On The Social Media Channels Of Allergy
Altamira Therapeutics Announces Dissemination of Positive Results From Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing and
Express News | Altamira Therapeutics Announces Filing Of Provisional Patent Application For OligoPhore Nanoparticles With SiRNA Targeting P65 Protein In Treatment Of Cancer And Inflammation
Express News | Altamira Therapeutics Announces Filing of Provisional Patent Application for Oligophore Nanoparticles With Sirna Targeting P65 Protein in Treatment of Cancer and Inflammation
Altamira Therapeutics Announces Publication of Positive Results From Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy
Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 18, 2024
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Investor Conference on April 18, 2024. The
Altamira Therapeutics Announces 2024 Annual Meeting
Diamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO)
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Altamira Therapeutics Ltd.
Express News | Altamira Therapeutics FY EPS $(16.47) Sales $284.47K Down From $330.37K YoY
No Data